CureLab Oncology publishes proof of concept demonstrating that its product can reduce metabolic disorders induced by excessive food consumption.

BOSTON, Aug. 9, 2017 /PRNewswire/ -- The journal Oncotarget published a pre-print of the research conducted by CureLab Oncology, Inc. The paper proposes the concept of the "vicious cycle" induced by high fat, high calorie diet and demonstrates that a new biological agent developed by the company may prevent and alleviate diet-induced disorders.

The work was performed on rats fed with a normal diet or high fat, high calorie food. Consumption of the unhealthy food resulted in metabolic misbalance, metabolic misbalance induced chronic inflammation, and chronic inflammation led to chemical alterations in the brain. Brain levels of the "satiety sensor", serotonin, were reduced while the serotonin-degrading enzyme, MAO, was elevated. As a result, animals consuming fatty food had to eat more and their body mass index grew significantly quicker. This, in turn, further exacerbates metabolic dysfunction – a positive feedback loop. "We called it the 'vicious cycle of a bad diet'"– said CureLab Oncology founder, Dr. Alexander Shneider, the senior author of the paper.

CureLab Oncology recently reported that their anti-cancer agent, Elenagen™, reduces chronic inflammation. The team of American, Ukrainian, Italian, and Russian scientists hypothesized that, by reducing chronic inflammation, Elenagen™ would break the vicious cycle reducing the negative effects of excessive diets. Experimental testing has supported the hypothesis. Administering Elenagen™ while simultaneously feeding rats with high calorie diet improved their metabolic parameters (levels of glucose, insulin, HbA1c, glucose tolerance), reduced chronic inflammation (less pro-inflammatory and more anti-inflammatory cytokines), and partially normalized levels of serotonin and MAO. Animals receiving Elenagen™ consumed less food and did not increase their body mass index to the same extent as rats receiving the same diet with no drug treatment. "We hope" – says Dr. Shneider – "that in few years we would bring to market a novel agent against type 2 diabetes and metabolic disorders as well as diseases accompanying diabetes and metabolic syndrome such as heart diseases, depression, or psoriasis. All of them are dependent on chronic inflammation." Notably, restoring serotonin and MAO levels are mechanisms of action of anti-depressant drugs. 

The paper is available online at http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=19840&pubmed-linkout=1.

About CureLab Oncology, Inc.

CureLab Oncology, Inc. is a Boston based private biotechnology company developing biological agents against cancer and chronic inflammation.

For more information please visit www.CureLabOncology.com.

SOURCE CureLab Oncology Inc.

Related Links

http://www.CureLabOncology.com